Popular on TelAve
- Sales Blueprint Architect Launches, Helping Sales Professionals, Business Owners, and Consultants Close More Business With AI - 724
- OneVizion Appoints Zebra Technologies CIO Matt Ausman to Board of Directors - 200
- Flexible Plan Investments Announces Retirement of Executive Vice President Renée Toth - 177
- Wings Air Helicopters Selected to Support VIP Transportation for Resorts World in New York
- ChargeOn Announces Conversational Payment Management Solution
- VC Fast Pitch and Steamwork Ventures Bring Startup & Investor Networking Event to Santa Barbara on October 8
- SafecomLink for Pactor – Hamradio Edition Launches in the WiMo Store
- Break the Resume Mold: Career Valet Changes How Executives Hunt for Jobs
- Work 365 Deepens TD SYNNEX Integration with Automated Azure Billing
- New Townhome Building Released at Heritage at South Brunswick, Offering Private Perimeter Setting and Water Views
China Cancer Drug Market will surpass US$ 30.5 Billion by the year end of 2025
TelAve News/10604869
Cancer is one of the biggest burdens for so many public health departments across the world and China has even more cancer patients due to growing population at rapid pace. According to GLOBCAN, nearly 2.9 Million new cancer deaths happened in China in the year 2018. If we talk about cancer incidence, this rate is much lower in China rather than United States and United Kingdom. But when we talk about mortality rate, China mortality rate is almost 30% to 40% higher than the United States and United Kingdom. Moreover, increasing diagnostic center, improving cancer treatment therapy and acceptance of targeted drug therapy will further boost the China cancer market in forecast period. However, expensive cancer drug and various side-effects will also hinder the market. According to Renub Research Analysis, China Cancer Drug Market will surpass US$ 30.5 Billion by the year end of 2025.
China cancer drug market has grown rapidly in historical period and it is expected to grow significantly during the forecast period. There are various factors that will help the market to outperform; rising ageing population in China, changes of lifestyle and food habits, rising incidence rate of several type of cancer, rise in tobacco smoking population due to expansion of urbanization in China, improving healthcare infrastructure and facilities in China, increasing per capita disposable income, rising per capita healthcare expenditure, improving awareness regarding cancer risk, potential due to emerging economies etc.
More on TelAve News
Renub Research report titled "China Cancer Drugs Market, by Drugs [Cytotoxic Drugs (Antimetabolities, Plant Alkaloids, Alkylating Agents), Targeted Drugs, Monoclonal Antibiotics, Hormonal Drugs, Traditional Chinese Medicine (TCM), & Others], Cancer (Lung, Stomach, Breast, Esophageal, Liver & Others), Therapy (Chemotherapy, Targeted Therapy, Hormonal Therapy & Others), Companies (Merck, Celgene, Eli Lilly, Roche & Sino BioPharma)" provides a complete analysis of China Anti-Cancer Drugs Market.
Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=china-cancer-drugs-market-p.php
China Cancer Drug Market Insight by Drug Type
In this report, China cancer drugs market is fragmented by drug type into six parts; Targeted Drugs, Cytotoxic Drugs, Monoclonal Antibiotics, Hormonal Drugs, TCM and Others. Cytotoxic Drugs type is further categorized into three parts; Antimetabolites, Plant Alkaloids and Alkylating Agents. Currently targeted drugs have more ability to kill malignant cells and it is quite popular because of higher success rate and efficacy.
China Cancer Drug Market Insight by Types of Cancer
In this report, we have done in-depth analysis of market by types of cancer; Lung, Stomach, Breast, Esophageal, Liver & Others.
More on TelAve News
China Cancer Drug Market Insight by Therapy
According Renub Research, targeted drug therapy is growing significantly in China due its higher efficacy and success rate than other therapy. In this report, we have design multi-dimensional approach to study all the cancer therapy which includes various important variables such as prime factors that support market growth, opportunities in each therapy, challenges faced by particular therapy etc.
Request a free Brochure copy of the report: https://www.renub.com/request-brochure-page.php?gturl=china-cancer-drugs-market-p.php
By Drugs
o Antimetabolities
o Plant Alkaloids
o Alkylating Agents
By Cancer
By Therapy
Companies Covered in the Report
If the information you seek is not included in the current scope of the study kindly share your specific requirements with our custom research team.
Contact Us
Email: info@renub.com
Phone: +1-678-302-0700
Web: www.renub.com
China cancer drug market has grown rapidly in historical period and it is expected to grow significantly during the forecast period. There are various factors that will help the market to outperform; rising ageing population in China, changes of lifestyle and food habits, rising incidence rate of several type of cancer, rise in tobacco smoking population due to expansion of urbanization in China, improving healthcare infrastructure and facilities in China, increasing per capita disposable income, rising per capita healthcare expenditure, improving awareness regarding cancer risk, potential due to emerging economies etc.
More on TelAve News
- Virtually Tour Heritage at South Brunswick's Resort-Style Living - Experience Indoor and Outdoor Amenities at Your Fingertips
- Derek Cook's Roofing Encourages Homeowners to Prepare for Fall Weather
- Boston Industrial Solutions Expands Product Offering with Pad Printing Pads and Silicone for Custom Pad Manufacturing
- Rodeo FX Originals Appoints Yvann Thibaudeau Head of Development & IP
- Modern Network Infrastructure with 6WIND vCGNAT
Renub Research report titled "China Cancer Drugs Market, by Drugs [Cytotoxic Drugs (Antimetabolities, Plant Alkaloids, Alkylating Agents), Targeted Drugs, Monoclonal Antibiotics, Hormonal Drugs, Traditional Chinese Medicine (TCM), & Others], Cancer (Lung, Stomach, Breast, Esophageal, Liver & Others), Therapy (Chemotherapy, Targeted Therapy, Hormonal Therapy & Others), Companies (Merck, Celgene, Eli Lilly, Roche & Sino BioPharma)" provides a complete analysis of China Anti-Cancer Drugs Market.
Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=china-cancer-drugs-market-p.php
China Cancer Drug Market Insight by Drug Type
In this report, China cancer drugs market is fragmented by drug type into six parts; Targeted Drugs, Cytotoxic Drugs, Monoclonal Antibiotics, Hormonal Drugs, TCM and Others. Cytotoxic Drugs type is further categorized into three parts; Antimetabolites, Plant Alkaloids and Alkylating Agents. Currently targeted drugs have more ability to kill malignant cells and it is quite popular because of higher success rate and efficacy.
China Cancer Drug Market Insight by Types of Cancer
In this report, we have done in-depth analysis of market by types of cancer; Lung, Stomach, Breast, Esophageal, Liver & Others.
More on TelAve News
- Phoenix 5/7 Emerges as a Genre-Fluid Artist Collective
- Massage Revolution Expands to Santa Monica With New Wilshire Boulevard Location
- "Warrior Defined" Event Brings Men Together in Charlotte, With Calls for Events Across the U.S
- Dion Abadi Publishes Free Collector Tips Hub for Art and Jewelry Buyers
- World-Renowned Body Language Expert Mark Bowden Headlines INSPIRE Northwest 2026 in Wenatchee, WA
China Cancer Drug Market Insight by Therapy
According Renub Research, targeted drug therapy is growing significantly in China due its higher efficacy and success rate than other therapy. In this report, we have design multi-dimensional approach to study all the cancer therapy which includes various important variables such as prime factors that support market growth, opportunities in each therapy, challenges faced by particular therapy etc.
Request a free Brochure copy of the report: https://www.renub.com/request-brochure-page.php?gturl=china-cancer-drugs-market-p.php
By Drugs
- Cytotoxic Drugs
o Antimetabolities
o Plant Alkaloids
o Alkylating Agents
- Targeted Drugs
- Monoclonal Antibiotics
- Hormonal Drugs
- Traditional Chinese Medicine (TCM)
- Others
By Cancer
- Lung Cancer
- Stomach Cancer
- Breast Cancer
- Esophageal Cancer
- Liver Cancer
- Others
By Therapy
- Chemotherapy
- Targeted Therapy
- Hormonal Therapy
- Others
Companies Covered in the Report
- Merck
- Celegene
- Eli Lilly
- Roche
- Sino BioPharma
If the information you seek is not included in the current scope of the study kindly share your specific requirements with our custom research team.
Contact Us
Email: info@renub.com
Phone: +1-678-302-0700
Web: www.renub.com
0 Comments
Latest on TelAve News
- Port St. Lucie REALTOR® Irene Pernice Earns SFR® Certification
- AMR and UAS Take the Stage at WorldSkills Shanghai 2026
- Biophysical Therapeutics brings longevity science to skincare with its new IF1 brand
- JoCa's Echoes of Haworth Sells Out on Opening Night in Mexico City; Artist Heads to San Luis Potosí and Miami Art Week
- Home2 Suites by Hilton Lee's Summit, MO Opens to Guests
- Shanghai Chengwei Semiconductor Equipment Launches High Precision Laboratory Central Gas Supply System
- Your Local Pro Expands National Service Network to 273+ Locations Across Plumbing, Cleaning, Landscaping and Hydrovac
- Acuvance Coker Study Finds Experience, Not Supply, Is the Biggest Advanced Practice Provider Workforce Challenge
- Building Smarter Networks with Cloud-Native Technology
- Uk Financial Moonshot Token™ Robinhood-chain Goes Live On Tokpie Exchange Tomorrow, With Solana Side Of UKFLMS To Follow In Global Listing Expansion
- Solid Earth's new "Welcome to Real Estate" campaign introduces RealtyID™: Know Before Your Open the Door
- Radio Drive's New Album Walk With Me Delivers Two GRAMMY® Submissions Across Rock and Alternative Categories
- Kaplan Morrell and Attorney Jacqui Condon Selected to Represent Professional Women's Soccer Players in Workers' Compensation Matters
- ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
- Lunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist Agreement
- Revenue Optics Names Prat Patibandla Director of Growth Marketing
- Independent Autopsies Are Changing Civil Cases: Kansas City Forensic Explains Why Families Are Seeking Second Opinions
- JEGS Launches Transformed Digital Commerce Platform Powered by PhaseZero
- Optimum Partners with ScreenCloud to Bring Enterprise Digital Signage to the Deskless Workforce
- Subject matter experts: Present your ideas at IISE Annual Conference 2027 in Louisville